Myeloid and Monocytic Leukemia, Phase II

Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

Volunteers
Health Professionals

What is the purpose of this trial?

Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Tarsheen Sethi

tarsheen.sethi@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Tarsheen Sethi, MD, MSc
Assistant Professor of Medicine (Hematology); Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine

Sub-Investigators

Last Updated
10/10/2024
Study HIC
#2000037447